Dernières nouvelles

Information non disponible

22 enregistrements « 1 de 3 »

Lalani AA, Kapoor A, Basappa NS, Bhindi B, Bjarnason GA, Bosse D, Breau RH, Canil CM, Cardenas LM, Castonguay V, Chavez-Munoz C, Chu W, Dudani S, Graham J, Heng DYC, Kollmannsberger C, Lattouf JB, Morgan S, Reaume MN, Richard PO, Swaminath A, Tanguay S, Wood LA, Lavallée LT

Adjuvant therapy for renal cell carcinoma: 2023 Canadian Kidney Cancer Forum consensus statement

Article de revue

Can Urol Assoc J, 17 (5), 2023.

Résumé | Liens:

Monk BJ, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Hurtado de Mendoza MO, Samouëlian V, Castonguay V, Arkhipov A, Tekin C, Li K, Martin Nguyen A, Monberg MJ, Colombo N, Lorusso D

Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial

Article de revue

Lancet Oncol, 24 (4), 2023.

Résumé | Liens:

Lacombe L, Hovington H, Brisson H, Mehdi S, Beillevaire D, Émond JP, Wagner A, Villeneuve L, Simonyan D, Ouellet V, Barrès V, Latour M, Aprikian A, Bergeron A, Castonguay V, Couture F, Chevalier S, Brimo F, Fazli L, Fleshner N, Gleave M, Karakiewicz PI, Lattouf JB, Trudel D, van der Kwast T, Mes-Masson AM, Pouliot F, Fradet Y, Audet-Walsh E, Saad F, Guillemette C, Lévesque E

UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways

Article de revue

Cancer Lett, 553 , 2023.

Résumé | Liens:

Nguyen EK, Lalani AKA, Ghosh S, Basappa NS, Kapoor A, Hansen AR, Heng D, Wood LA, Castonguay V, Soulières D, Winquist E, Canil C, Bjarnason GA, Breau RH, Pouliot F, Swaminath, A

Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System

Article de revue

Adv Radiat Oncol, 7 (4), 2022.

| Liens:

Choueiri TK, Kluger H, George S, Tykodi SS, Kuzel TM, Perets R, Nair S, Procopio G, Carducci MA, Castonguay V, Folefac E, Lee CH, Hotte SJ, Miller WH, Saggi SS, Lee CW, Desilva H, Bhagavatheeswaran P, Motzer RJ, Escudier B

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy

Article de revue

J Immunother Cancer, 10 (11), 2022.

Résumé | Liens:

Nguyen EK, Lalani AKA, Ghosh S, Basappa NS, Kapoor A, Hansen AR, Kollmannsberger C, Heng D, Wood LA, Castonguay V, Soulières D, Winquist E, Canil C, Graham J, Bjarnason GA, Breau RH, Pouliot F, Swaminath A

Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System

Article de revue

Adv Radiat Oncol, 7 (4), 2022.

Résumé | Liens:

Thana M, Basappa NS, Ghosh S, Kollmannsberger CK, Heng DYC, Hansen AR, Graham J, Soulières D, Reaume MN, Lalani AA, Castonguay V, Bjarnason GA, Patenaude F, Breau RH, Pouliot F, Kapoor A, Wood LA

Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients

Article de revue

Clin Genitourin Cancer, 20 (3), 2022.

Résumé | Liens:

Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Yanez E, Gumus M, Olivera Hurtado de Mendoza M, Samouelian V, Castonguay V, Arkhipov A, Toker S, Li K, Keefe SM, Monk BJ,

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Article de revue

Obstet Gynecol Surv, 77 (1), 2022.

| Liens:

Zhang H, Basappa NS, Ghosh S, Joy I, Lalani AKA, Hansen AR, Heng DYC, Castonguay V, Kollmannsberger CK, Winquist E, Wood L, Bjarnason GA, Breau RH, Kapoor A, Graham J

Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis)

Article de revue

Kidney Cancer, 5 (1), 2021.

| Liens:

Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Yañez E, Olivera Hurtado de Mendoza M, Castonguay V, Arkhipov A, Toker S, Li K, Keefe SM, Monk BJ,

Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Article de revue

N Engl J Med, 385 (20), 2021.

Résumé | Liens:

22 enregistrements « 1 de 3 »
Signaler des ajouts ou des modifications

Projets terminés récemment

  • An International Phase III Randomised Study to Evaluate the Efficacy of Maintenance Therapy with Olaparib and Cediranib ... Following a Response to Platinum-Based Chemotherapy , du 2021-01-22 au 2022-01-21
Information provenant du registre des projets de recherche de l'Université Laval